Murepavadin

CAS No. 944252-63-5

Murepavadin( POL7080 | POL 7080 )

Catalog No. M16763 CAS No. 944252-63-5

Murepavadin (POL7080)?is a highly potent, specific, macrocycle Pseudomonas antibiotic for the treatment of bacterial infections caused by Pseudomonas aeruginosa.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Murepavadin
  • Note
    Research use only, not for human use.
  • Brief Description
    Murepavadin (POL7080)?is a highly potent, specific, macrocycle Pseudomonas antibiotic for the treatment of bacterial infections caused by Pseudomonas aeruginosa.
  • Description
    Murepavadin (POL7080)?is a highly potent, specific, macrocycle Pseudomonas antibiotic for the treatment of bacterial infections caused by Pseudomonas aeruginosa.Bacterial Infection Phase 3 Clinical.
  • In Vitro
    Murepavadin has activity against P. aeruginosa with MIC50 and MIC90 values both of 0.12 mg/L.Murepavadin inhibits megalin-mediated uptake of gentamicin in vitro with an IC50 value of 5.84 μM.
  • In Vivo
    Murepavadin (s.c.; 0-100 mg/kg) is active in pre-clinical animal models including infections with XDR isolates. Animal Model:murine models of P. aeruginosa infectionDosage:0-100 mg/kg Administration:Subcutaneous, q24h or q12h Result:Resulted in an increase in survival rate to 100% and showed significantly lower CFU levels both in the blood and in the peritoneal fluid at 2 and 10 mg/kg 1 h post-infection.Animal Model:Mouse, rat, rabbit, and monkey Dosage:0-5 mg/kg Administration:Intraperitoneal or subcutaneous, single Result:Followed a two-compartment model following intravenous administration and decline of plasma concentrations.Distributed into the aqueous phase of the body, and systemic plasma clearance (CL) values were similar to the species-specific glomerular filtration rates (GFRs) .Had high bioavailability (67.79%) after subcutaneous (s.c.) administration in rats but had low oral bioavailability (<0.01%).Had a linear relationship between ELF AUC and unbound plasma AUC in mouse.
  • Synonyms
    POL7080 | POL 7080
  • Pathway
    GPCR/G Protein
  • Target
    Antibacterial
  • Recptor
    Antibacterial
  • Research Area
    Infection
  • Indication
    Bacterial Infection

Chemical Information

  • CAS Number
    944252-63-5
  • Formula Weight
    1553.837
  • Molecular Formula
    C73H112N22O16
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2CCCC2C(=O)N3CCCC3C(=O)NC(C(=O)NC(C(=O)N1)CC4=CNC5=CC=CC=C54)C(C)O)CO)C)CCN)CCN)CC6=CNC7=CC=CC=C76)CCN)CCN)CCCN)CCN
  • Chemical Name
    cyclo[Ala-Ser-D-Pro-Pro-Thr-Trp-Ile-Dab-Orn-D-Dab-Dab-Trp-Dab-Dab]

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Bassetti M, et al. Curr Opin Infect Dis. 2018 Jan 13. doi: 10.1097/QCO.0000000000000438.
molnova catalog
related products
  • 1-Dodecylimidazole

    1-Dodecylimidazole (N-Dodecylimidazole) is a lysosomotropic detergent and a cytotoxic agent. 1-Dodecylimidazole causes cell death by its acid-dependent accumulation in lysosomes, disruption of the lysosomal membrane, and releaseof cysteine proteases into the cytoplasm.

  • Q203

    A novel potent anti-tuberculosis agent targeting cytochrome b subunit qcrB, inhibits M. tuberculosis H37Rv with MIC50 of of 2.7 nM.

  • Clarithromycin

    An antibiotic by acting as a protein synthesis inhibitor.